Caister Academic Press

Hepatitis C Virus Drug Pipeline Overview and Clinical Trial Design

Jean-Michel Pawlotsky
from: Hepatitis C: Antiviral Drug Discovery and Development (Edited by: Seng-Lai Tan and Yupeng He). Caister Academic Press, U.K. (2011)

Abstract

In the last decade, insights into the virology of hepatitis C virus (HCV) have unraveled several targets for potential novel therapeutics that, unlike interferon (IFN)-alpha and ribavirin, are specifically targeted to HCV. Many such direct-acting antiviral (DAA) drugs are at the preclinical developmental stage and several are in clinical development. Initial clinical trials using some of these inhibitors, either alone or in combination with pegylated IFN-alpha and ribavirin, have yielded encouraging results read more ...
Access full text
Related articles ...